Skip to main content


Immunobiology and immunotherapy

Section edited by Alessandra Cesano

This section aims to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

As immunology has evolved to be a central discipline connected to a wide range of therapeutic areas, the number and diversity of platform technologies has also increased, spanning small molecules, biologics, microbial vectors and cells. Such levels of activity require appropriate means to share new knowledge and to catalyze the development of the field. This section aims to provide such a platform and welcomes submissions across all disciplines, including inflammation, autoimmunity, transplantation, metabolic disorders.

The section was founded with the Society for Immunotherapy of Cancer (SITC) under the title "Tumor immunology and biological cancer therapy" and Edited by Pedro Romero.

Page 7 of 7

  1. Content type: Research

    Several immunotherapeutic approaches rely on antigen-specific T-cells. Restrictions in the T-cell receptor (TCR) repertoire were reported as indicator of anti-tumor cytotoxic T-lymphocyte (CTL) response in var...

    Authors: Sebastian Ochsenreither, Alberto Fusi, Susanne Wojtke, Antonia Busse, Natascha C Nüssler, Eckhard Thiel, Ulrich Keilholz and Dirk Nagorsen

    Citation: Journal of Translational Medicine 2010 8:35

    Published on:

  2. Content type: Research

    Type-1 T cells are critical for effective anti-tumor immune responses. The recently discovered microRNAs (miRs) are a large family of small regulatory RNAs that control diverse aspects of cell function, includ...

    Authors: Kotaro Sasaki, Gary Kohanbash, Aki Hoji, Ryo Ueda, Heather A McDonald, Todd A Reinhart, Jeremy Martinson, Michael T Lotze, Francesco M Marincola, Ena Wang, Mitsugu Fujita and Hideho Okada

    Citation: Journal of Translational Medicine 2010 8:17

    Published on:

  3. Content type: Research

    Although an abundance of evidence has indicated that tumor-associated macrophages (TAMs) are associated with a favorable prognosis in patients with colon cancer, it is still unknown how TAMs exert a protective...

    Authors: Qiang Zhou, Rui-Qing Peng, Xiao-Jun Wu, Qing Xia, Jing-Hui Hou, Ya Ding, Qi-Ming Zhou, Xing Zhang, Zhi-Zhong Pang, De-Sen Wan, Yi-Xin Zeng and Xiao-Shi Zhang

    Citation: Journal of Translational Medicine 2010 8:13

    Published on:

  4. Content type: Research

    Glycoprotein-96, a non-polymorphic heat-shock protein, associates with intracellular peptides. Autologous tumor-derived heat shock protein-peptide complex 96 (HSPPC-96) can elicit potent tumor-specific T cell ...

    Authors: Omar Eton, Merrick I Ross, Mary Jo East, Paul F Mansfield, Nicholas Papadopoulos, Julie A Ellerhorst, Agop Y Bedikian and Jeffrey E Lee

    Citation: Journal of Translational Medicine 2010 8:9

    Published on:

  5. Content type: Research

    Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations i...

    Authors: Osama E Rahma, Ed Ashtar, Ramy Ibrahim, Antoun Toubaji, Barry Gause, Vincent E Herrin, W Marston Linehan, Seth M Steinberg, Frank Grollman, George Grimes, Sarah A Bernstein, Jay A Berzofsky and Samir N Khleif

    Citation: Journal of Translational Medicine 2010 8:8

    Published on:

  6. Content type: Research

    The conventional treatment protocol in high-intensity focused ultrasound (HIFU) therapy utilizes a dense-scan strategy to produce closely packed thermal lesions aiming at eradicating as much tumor mass as poss...

    Authors: Fang Liu, Zhenlin Hu, Lei Qiu, Chun Hui, Chao Li, Pei Zhong and Junping Zhang

    Citation: Journal of Translational Medicine 2010 8:7

    Published on:

  7. Content type: Research

    Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or ...

    Authors: Antonia Busse, Anne Letsch, Carmen Scheibenbogen, Anika Nonnenmacher, Sebastian Ochsenreither, Eckhard Thiel and Ulrich Keilholz

    Citation: Journal of Translational Medicine 2010 8:5

    Published on:

  8. Content type: Research

    Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cance...

    Authors: Ping Jin, Tae Hee Han, Jiaqiang Ren, Stefanie Saunders, Ena Wang, Francesco M Marincola and David F Stroncek

    Citation: Journal of Translational Medicine 2010 8:4

    Published on:

  9. Content type: Research

    Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Dox...

    Authors: Ioannis Alagkiozidis, Andrea Facciabene, Carmine Carpenito, Fabian Benencia, Zdenka Jonak, Sarah Adams, Richard G Carroll, Phyllis A Gimotty, Rachel Hammond, Gwen-äel Danet-Desnoyers, Carl H June, Daniel J Powell Jr and George Coukos

    Citation: Journal of Translational Medicine 2009 7:104

    Published on:

  10. Content type: Research

    CD40 activation of antigen presenting cells (APC) such as dendritic cells (DC) and B cells plays an important role in immunological licensing of T cell immunity. Agonist CD40 antibodies have been previously sh...

    Authors: Erica L Carpenter, Rosemarie Mick, Jens Rüter and Robert H Vonderheide

    Citation: Journal of Translational Medicine 2009 7:93

    Published on:

Annual Journal Metrics